Ketamine Assisted Psychotherapy for Opioid Use Disorder

Stage 1 randomised, parallel-group trial comparing MORE combined with two ketamine-assisted psychotherapy sessions (MORE+KAP) versus MORE alone in patients receiving medications for OUD (e.g., buprenorphine).

MORE+KAP participants receive two intramuscular ketamine sessions (0.5–1.5 mg/kg) alongside the 8-week MORE programme; primary outcomes assess preliminary efficacy of KAP as an adjunct to MORE and secondary aims examine psychobiological mediators.